Sun Pharma tumbles after declaring Q4 result

Sun Pharmaceutical Industries lost 8.41% to Rs 884.50 at 10:35 IST on BSE after consolidated net profit fell 44% to Rs 888.05 crore on 53.8% surge in total income to Rs 6540.74 crore in Q4 March 2015 over Q4 March 2014.

The result was announced after market hours on Friday, 29 May 2015.

Meanwhile, the S&P BSE Sensex was up 26.87 points or 0.01% at 27,855.31

On BSE, so far 8.03 lakh shares were traded in the counter as against average daily volume of 5.42 lakh shares in the past one quarter.

The stock hit a high of Rs 918 and a low of Rs 869.50 so far during the day. The stock had hit a record high of Rs 1,200.70 on 7 April 2015. The stock had hit a 52-week low of Rs 582.50 on 29 May 2014.

The large-cap pharma firm has equity capital of Rs 240.64 crore. Face value per share is Re 1.

Sun Pharmaceutical Industries said that the financials for Q4 March 2015 include the impact of the merger of the erstwhile Ranbaxy Laboratories into the company, and hence are not strictly comparable.

Sun Pharmaceutical Industries' EBITDA stood at Rs 880 crore resulting in EBITDA margin of 14.3% in Q4 March 2015. EBITDA as well as net profit were adversely impacted by a few items, relating to professional charges, harmonization of policies of erstwhile Ranbaxy with the company, etc, Sun Pharmaceutical Industries said. The impact of these items appearing above EBITDA was approximately 10% of net sales and on items appearing below EBITDA was approximately 7% of net sales, the company said.

Sales of branded prescription formulations in India was Rs 1569 crore in Q4 March 2015. Sales in the US was $488 million in Q4 March 2015. Sales in emerging markets was $123 million for Q4 March 2015. Formulation sales in Rest of World (ROW) markets excluding US and Emerging Markets was $84 million in Q4 March 2015.

Dilip Shanghvi, Managing Director of Sun Pharmaceutical Industries' said that post the completion of the merger, the company has commenced the integration of Ranbaxy. The company's performance was impacted due to various one-time charges, mainly on account of the Ranbaxy merger as well as due to price erosion for some products in the US. It also reflected the impact of supply constraints related to the on-going remediation efforts at some of the company's facilities, Dilip Shanghvi said. The company is pledged to being 100% cGMP compliant and is fully responsible towards customers and patients across the world for quality products, he added.

Sun Pharmaceutical Industries is an international specialty pharmaceutical company.

Powered by Capital Market - Live News